Hansoh Pharma (03692): HS-10541 tablets obtained the drug clinical trial approval notification letter issued by the National Medical Products Administration.
Hansun Pharmaceuticals (03692) announced that the group's independently developed new drug HS-10541 tablet has obtained the drug clinical trial approval notification issued by the National Medical Products Administration (NMPA) of China, and plans to conduct clinical trials for the treatment of late-stage solid tumors with KRAS G12C mutation.
HANSOH PHARMA (03692) announced that the group's independently developed new drug HS-10541 tablet has been granted a drug clinical trial approval notification by the National Medical Products Administration (NMPA) of China, and plans to conduct a clinical trial for the treatment of late-stage solid tumors with KRAS G12C mutation.
Related Articles
China Railway (00390): "21 CRC Y4" will be fully redeemed on June 18th.
On May 13, JST GROUP (06687) spent HKD 845,600 to repurchase 57,300 shares.
On May 13, BLACK SESAME (02533) repurchased 1.2838 million shares for 22.645 million Hong Kong dollars.
China Railway (00390): "21 CRC Y4" will be fully redeemed on June 18th.
On May 13, JST GROUP (06687) spent HKD 845,600 to repurchase 57,300 shares.
On May 13, BLACK SESAME (02533) repurchased 1.2838 million shares for 22.645 million Hong Kong dollars.
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
11/05/2026
